MREO
Mereo BioPharma Group plcNASDAQHealthcare$0.32-1.19%ClosedMarket Cap: $51.1M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.23
P/S
100.94
EV/EBITDA
-0.22
DCF Value
$0.26
FCF Yield
-62.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
73.2%
Operating Margin
-8100.3%
Net Margin
-8375.6%
ROE
-83.0%
ROA
-91.2%
ROIC
-96.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-8.8M | $-7.4M | $-0.05 | — |
| FY 2025 | $500.0K | 73.4% | $-40.5M | $-41.9M | $-0.26 | — |
| Q3 2025 | $0.00 | -Infinity% | $-10.0M | $-7.0M | $-0.04 | — |
| Q2 2025 | $500.0K | 73.6% | $-10.5M | $-14.6M | $-0.09 | — |
| Q1 2025 | $0.00 | NaN% | $-11.2M | $-12.9M | $-0.08 | — |
| Q4 2024 | $0.00 | -Infinity% | $-15.1M | $-7.0M | $-0.05 | — |
| FY 2024 | $0.00 | NaN% | $-47.4M | $-43.3M | $-0.29 | — |
| Q3 2024 | $0.00 | NaN% | $-9.4M | $-15.0M | $-0.10 | — |
| Q2 2024 | $0.00 | NaN% | $-12.8M | $-12.3M | $-430.59 | — |
| Q1 2024 | $0.00 | NaN% | $-9.9M | $-9.0M | $-319.56 | — |
| Q4 2023 | $1.0M | 127.3% | $-7.1M | $-9.1M | $-278.56 | — |
| FY 2023 | $10.0M | 74.3% | $-28.4M | $-29.5M | $-1,100.22 | — |